Business Context and Reporting Period
This Form 8-K is a current report filed by Aerovate Therapeutics, Inc. (not Jade Biosciences, Inc.) on July 15, 2021. The registrant is a Delaware corporation with its principal executive offices in Boston, Massachusetts. The company is classified as an emerging growth company and its common stock trades on the Nasdaq Global Market under the symbol AVTE.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of Allison Dorval as a member of the Board of Directors, effective July 15, 2021. Key governance changes include:
- Board Appointment: Ms. Dorval was appointed as a Class II director, serving until the 2023 annual meeting.
- Audit Committee Leadership: Ms. Dorval was appointed Chair of the Audit Committee and is designated as an "audit committee financial expert."
- Resignations: Joshua Resnick, M.D., resigned as a member of the Audit Committee, and Maha Katabi, Ph.D., resigned as Chair of the Audit Committee (though Dr. Katabi remains a member).
- Committee Composition: The Audit Committee now consists of Ms. Dorval (Chair), Dr. Katabi, and Mr. Iwicki.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of business risks. Regarding compensation, Ms. Dorval will receive cash compensation and an equity award consistent with the Company's Non-Employee Director Compensation Policy. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the correct registrant name is Aerovate Therapeutics, Inc. (AVTE), as the request metadata incorrectly referenced Jade Biosciences, Inc.
- Confirm the independence status of the new Audit Committee Chair, Allison Dorval, under Nasdaq listing standards.
- Review the press release filed as Exhibit 99.1 for additional details on Ms. Dorval's background.
- Note that this filing provides no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.